ABSTRACT
Germline pathogenic variants in TP53 are associated with Li-Fraumeni syndrome (LFS), an autosomal dominant cancer predisposition disorder associated with high risk of malignancy, including early onset breast cancers, sarcomas, adrenocortical carcinomas and brain tumors. Intense cancer surveillance for individuals with TP53 germline pathogenic variants has been shown to decrease mortality; therefore, accurate and consistent classification of variants across clinical and research laboratories is crucial to patient care. Here, we describe the work performed by the Clinical Genome Resource TP53 Variant Curation Expert Panel (ClinGen TP53 VCEP) focused on specifying the American College of Medical Genetics and Genomics and the Association for Molecular Pathology (ACMG/AMP) guidelines for germline variant classification to the TP53 gene. Specifications were applied to twenty ACMG/AMP criteria while nine were deemed not applicable. The original strength level for ten criteria was also adjusted due to current evidence. Use of the TP53-specific guidelines and sharing of clinical data amongst experts and clinical laboratories led to a decrease in variants of uncertain significance from 28% to 12% in comparison with the original guidelines. The ClinGen TP53 VCEP recommends the use of these TP53-specific ACMG/AMP guidelines as the standard strategy for TP53 germline variant classification.
Competing Interest Statement
The following authors have no conflicts of interest to disclose: K.L., M.O., K.C.A., S.B., A.K.M.F., M.F., B.A.S., L.W., L.Z. The following authors have made extensive contributions to the TP53 literature and have previously published assertions on TP53 variants: C.F., P.L.M., L.D.A., D.G.E., P.J., K.M., T.P.S., A.B.S., S.A.S. The following authors are an employee, trainee or consultant for a commercial laboratory that offers genetic testing for TP53: T.P., R.H., K.M., S.E.P. J.M. is an employee of GeneDx/BioReference Laboratories, Inc./OPKO Health and has a salary as the only disclosure. The PERCH software, for which B.J.F. is the inventor, has been non-exclusively licensed to Ambry Genetics Corporation for their clinical genetic testing services and research. B.J.F. also reports funding and sponsorship to his institution on his behalf from Pfizer Inc. and Regeneron Genetics Center LLC.
Funding Statement
This Expert Panel is funded by National Human Genome Research & National Cancer Institutes (1U41HG006834, 1U01HG007437, 1U01HG007436, HHSN261200800001E, U41HG009650). The work of C.F. was supported by a University of Queensland (UQ) International Scholarship from the UQ School of Medicine. The work of M.F., K.C.A., and S.A.S. was supported by the intramural research program of the Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health. The work of A.B.S. was supported by Australian National Health and Medical Research funding (ID1061779, ID1161589). The work of D.G.E. was supported by the NIHR Manchester Biomedical Research Centre (IS-BRC-1215–20007). The work of T.P.S. was supported by NIH-NCI K08CA234394 and R01CA242218.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Most of the data that support the findings of this study are openly available in the IARC TP53 Database at https://p53.iarc.fr (version R20, July 2019). Other data supporting the findings of this study are not publicly available due to private or ethical restrictions. The publicly available Clinical Genome Resource (ClinGen) Evidence Repository contains all of the curated evidence for the variants submitted to ClinVar (e.g., https://erepo.clinicalgenome.org/evrepo/ui/interpretation/7b4332f9-03a6-43f1-afde-508d91bd92d5).
